- Home
- KPRX vs PET Comparison
KPRX vs PET Comparison
Compare KPRX & PET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- PET
- Stock Information
- Founded
- KPRX 1998
- PET 2015
- Country
- KPRX United States
- PET United States
- Employees
- KPRX N/A
- PET N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PET EDP Services
- Sector
- KPRX Health Care
- PET Technology
- Exchange
- KPRX Nasdaq
- PET Nasdaq
- Market Cap
- KPRX 9.1M
- PET 7.4M
- IPO Year
- KPRX N/A
- PET N/A
- Fundamental
- Price
- KPRX $3.08
- PET $0.14
- Analyst Decision
- KPRX Strong Buy
- PET Strong Buy
- Analyst Count
- KPRX 1
- PET 4
- Target Price
- KPRX $10.00
- PET $4.13
- AVG Volume (30 Days)
- KPRX 1.3M
- PET 2.1M
- Earning Date
- KPRX 05-09-2025
- PET 05-12-2025
- Dividend Yield
- KPRX N/A
- PET N/A
- EPS Growth
- KPRX N/A
- PET N/A
- EPS
- KPRX N/A
- PET N/A
- Revenue
- KPRX $20,000.00
- PET $62,453,000.00
- Revenue This Year
- KPRX N/A
- PET $7.87
- Revenue Next Year
- KPRX N/A
- PET $122.23
- P/E Ratio
- KPRX N/A
- PET N/A
- Revenue Growth
- KPRX N/A
- PET N/A
- 52 Week Low
- KPRX $2.51
- PET $0.08
- 52 Week High
- KPRX $5.55
- PET $1.79
- Technical
- Relative Strength Index (RSI)
- KPRX 48.79
- PET 46.08
- Support Level
- KPRX $2.90
- PET $0.14
- Resistance Level
- KPRX $4.18
- PET $0.17
- Average True Range (ATR)
- KPRX 0.26
- PET 0.01
- MACD
- KPRX 0.00
- PET 0.00
- Stochastic Oscillator
- KPRX 19.12
- PET 21.89
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About PET Wag! Group Co.
Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools and pet wellness plans.